A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering ...

Researchers developed FLAV-27, an epigenetic drug that inhibits G9a to restore gene expression in Alzheimer’s models. The treatment reduced amyloid and tau, improved cognition and synaptic function, ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease. Unlike ...

A new drug, FLAV-27, targets epigenetic changes in Alzheimer’s. In preclinical studies, the drug reduced levels of ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease.

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for ...

Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the very early stages of Alzheimer's disease. Published in Translational ...

A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the ...

More than 7 million Americans currently have Alzheimer’s disease (AD). That’s according to the Alzheimer’s Association. One out of every nine seniors over age 65 will experience some degree of ...

Add Yahoo as a preferred source to see more of our stories on Google. Drugs that halt Alzheimer’s should be rolled out more widely, Baroness Casey has said. In her first speech since she was appointed ...

Over seven million Americans currently have Alzheimer disease (AD). That’s according to the Alzheimer’s Association. One out of every nine seniors over 65 will experience some degree of dementia.